Malignancies, prothrombotic mutations, and the risk of venous thrombosis

JAMA

Volumn 293, Issue 6, 2005, Pages 715-722

  Blom, Jeanet W ^a   Doggen, Carine J M ^a   Osanto, Susanne ^a   Rosendaal, Frits R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER; CASE CONTROL STUDY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM CANCER; FEMALE; GENE MUTATION; GENETIC RISK; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HETEROZYGOTE; HUMAN; LEG THROMBOSIS; LUNG CANCER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORBIDITY; NETHERLANDS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SKIN CANCER; STATISTICAL ANALYSIS; URINARY TRACT CANCER; VEIN THROMBOSIS;

EID: 13444256137     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.6.715     Document Type: Article

References (27)

1. Trousseau A. Phlegmasia Alba Dolens: Lectures on Clinical Medicine. London, England: The New Sydenham Society; 1868:5:281-331.
2. Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet. 1998;351:1077-1080.
3. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LI III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809-815.
4. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost. 2002;87:575-579.
5. Sörensen HT, Melemkjær L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343: 1846-1850.
6. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: part 1. Thromb Haemost. 1996;76:651-662.
7. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
8. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993;342: 1503-1506.
9. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
10. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999;353:1167-1173.
11. Büller HR, van der Meer J, Oudkerk M. CBO guideline deep venous thrombosis and pulmonary embolism; revision of the earlier guidelines: Dutch Organization for Quality Assurance in Hospitals [in Dutch]. Ned Tijdschr Geneeskd. 2000;144:1531-1537.
12. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
13. Gomez E; van der Poel SC, Jansen JH, van der Reijden BA, Lowenberg B. Rapid simultaneous screening of factor V Leiden and G20210A prothrombin variant by multiplex polymerase chain reaction on whole blood. Blood. 1998;91:2208-2209.
14. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet. 1955;19:251-253.
15. Khoury MJ, Flanders WD. Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with no controls! Am J Epidemiol. 1996;144:207-213.
16. Cogo A, Bernardi E, Prandoni P, et al. Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch Intern Med. 1994;154:164-168.
17. Monreal M, Fernandez-Llamazares J, Perandreu J, Urrutia A, Sahuquillo JC, Contel E. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost. 1997;78:1316-1318.
18. Nordström M, Lindblad B, Anderson H, Bergqvist D, Kjellström T. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ. 1994;308: 891-894.
19. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78:285-291.
20. Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost. 1999;25:173-182.
21. Falanga A. Mechanisms of hypercoagulation in malignancy and during chemotherapy. Haemostasis. 1998;28(suppl S3):50-60.
22. Francis JL, Biggerstaff J, Amirkhosravi A. Hemostasis and malignancy. Semin Thromb Hemost. 1998;24:93-109.
23. Gale AJ, Gordon SG. Update on tumor cell procoagulant factors. Acta Haematol. 2001;106:25-32.
24. Otterson GA, Monahan BP, Harold N, Steinberg SM, Frame JN, Kaye FJ. Clinical significance of the FV: Q506 mutation in unselected oncology patients. Am J Med. 1996;101:406-412.
25. Pihusch R, Danzl G, Scholz M, et al. Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer. 2002;94:3120-3126.
26. Thodiyil PA, Walsh DC, Kakkar AK. Thromboprophylaxis in the cancer patient. Acta Haematol. 2001;106:73-80.
27. Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with of without malignancy. Thromb Haemost. 2000;84:805-810.